More on EWTX
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $35.21 |
|
|||
| Open | $35.71 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $36.84 | ||||
| Day Low | $30.84 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 3,305,615 | ||||
- Biotech Bulls Stampede as Clinical Wins and Milestones Fuel Momentum
- Truist Securities Reiterates Buy Rating on Edgewise Therapeutics (EWTX)
- Leerink: 'CIRRUS Part D data continue to look supportive of EDG-7500’s potential'
- SpaceX, Rackspace surge premarket; Edgewise Therapeutics, Huntsman fall
- EDGEWISE reports Phase 2 HCM trial results for EDG-7500
- Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)
- Form 8-K Edgewise Therapeutics, For: Jun 04
- Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
- Edgewise Therapeutics (EWTX) PT Lowered to $48 at RBC Capital
- Edgewise Therapeutics (EWTX) PT Raised to $66 at Raymond James
Entities mentioned with ewtx
- FDA | View Related Stories »
- Twitter | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- 13G | View Related Stories »
- Earnings | View Related Stories »
- JPMorgan | View Related Stories »
- Show More...
